inVentiv Health, the US-based provider of clinical development, commercialisation and consulting services, has renamed PharmaNet/i3, its clinical research organisation (CRO) incorporating companies acquired in May and January 2011 respectively, to inVentiv Health Clinical.
The new identity reflects closer alignment between the clinical segment and inVentiv's commercial and consulting services, the parent company explained.
As such, it demonstrates “a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services”, noted Paul Meister, chief executive officer (CEO) at inVentiv Health.
Clients will now have access to “broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialistion”, Meister added.
Hill at the helm
Heading up iVentiv Health Clinical is Raymond Hill, who was appointed to that role in December 2012. Hill was previously CEO of Pharmaceutical Product Development (PPD).
He stepped down from that position less than three months after taking the reins at PPD, once the US-based contract research organisation had completed its transition to a private company owned by global investment firms The Carlyle Group and Hellman & Friedman. Before that, Hill was president of IMS Consulting Group.
“By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry,” Hill claimed.
He cited the business’s ability to help clients in late-stage trials “by tapping both digital and adherence experts from other inVentiv companies. Through this approach we can help our clients simplify complex health economics and outcomes research trials”.
inVentiv Health Clinical now draws on 7,000 employees in more than 36 countries worldwide. Its previous incarnation as PharmaNet/i3 reflected the acquisitions in quick succession of Ingenix’s i3 clinical development businesses and of PharmaNet Development Group during the first half of 2011.